Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics

It was predicted that the biological era might alter the natural history of Crohn’s disease, preventing the well-documented inflammation–fibrosis–fistulisation sequence. However, despite the development of novel biological therapies, average efficacy at 1 year remains at 30–50%, with this number dec...

Full description

Bibliographic Details
Main Authors: Susanna Meade, Raphael P. Luber, Gokul Tamilarasan, Eoin Dinneen, Peter M. Irving, Mark A. Samaan
Format: Article
Language:English
Published: European Medical Journal 2021-03-01
Series:European Medical Journal
Subjects:
Online Access:https://www.emjreviews.com/gastroenterology/article/emerging-treatments-for-crohns-disease-cells-surgery-and-novel-therapeutics/
id doaj-6372607202774489b7f85a62cf4b8cda
record_format Article
spelling doaj-6372607202774489b7f85a62cf4b8cda2021-04-06T14:55:19ZengEuropean Medical JournalEuropean Medical Journal2397-67642021-03-01614958Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics Susanna Meade0Raphael P. Luber1Gokul Tamilarasan2Eoin Dinneen3Peter M. Irving4Mark A. Samaan5Inflammatory Bowel Disease Unit, Guy’s and St Thomas’ Hospital, London, UKInflammatory Bowel Disease Unit, Guy’s and St Thomas’ Hospital, London, UK Royal Prince Alfred Hospital, University of Sydney, Sydney, AustraliaDivision of Surgery and Interventional Sciences, University College London, UKInflammatory Bowel Disease Unit, Guy’s and St Thomas’ Hospital, London, UK; School of Immunology and Microbial Sciences, King’s College London, UKInflammatory Bowel Disease Unit, Guy’s and St Thomas’ Hospital, London, UKIt was predicted that the biological era might alter the natural history of Crohn’s disease, preventing the well-documented inflammation–fibrosis–fistulisation sequence. However, despite the development of novel biological therapies, average efficacy at 1 year remains at 30–50%, with this number decreasing as second-line therapies are regularly required. Currently, new advanced therapies are under investigation to provide alternatives to available treatments. In addition, novel, nonpharmacological strategies are also being explored. Surgical intervention, currently inevitable in a significant proportion of patients, necessitates that prevention of postoperative recurrence is an important research focus and recent studies have shed light on the long-term efficacy of early operative interventions and emerging surgical techniques. Cellular therapies, including stem cell therapy for perianal disease, stem cell transplantation, and harnessing the therapeutic potential of regulatory T cells, are in various stages of development. These could conceivably change the landscape of Crohn’s disease management. Dietetic interventions offer a lower risk alternative that may be used as an adjunct to other therapies or where immunosuppression is unfavourable. Choosing between these therapeutic options depends on multiple factors, including the associated risk–benefit profile, available alternatives, as well as patient preference. In practice, optimal management is guided by a multidisciplinary team where pharmacological, nonpharmacological, and surgical strategies can be simultaneously explored. This narrative review aims to provide an update on advanced therapies under investigation in clinical trials and offer insights into novel, nonpharmacological approaches with a focus on interventions entering late-phase trials that will be relevant to clinical practice in the near future.https://www.emjreviews.com/gastroenterology/article/emerging-treatments-for-crohns-disease-cells-surgery-and-novel-therapeutics/crohn’s diseaseinflammatory bowel diseasetreatments/therapiessurgery
collection DOAJ
language English
format Article
sources DOAJ
author Susanna Meade
Raphael P. Luber
Gokul Tamilarasan
Eoin Dinneen
Peter M. Irving
Mark A. Samaan
spellingShingle Susanna Meade
Raphael P. Luber
Gokul Tamilarasan
Eoin Dinneen
Peter M. Irving
Mark A. Samaan
Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
European Medical Journal
crohn’s disease
inflammatory bowel disease
treatments/therapies
surgery
author_facet Susanna Meade
Raphael P. Luber
Gokul Tamilarasan
Eoin Dinneen
Peter M. Irving
Mark A. Samaan
author_sort Susanna Meade
title Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
title_short Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
title_full Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
title_fullStr Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
title_full_unstemmed Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
title_sort emerging treatments for crohn's disease: cells, surgery, and novel therapeutics
publisher European Medical Journal
series European Medical Journal
issn 2397-6764
publishDate 2021-03-01
description It was predicted that the biological era might alter the natural history of Crohn’s disease, preventing the well-documented inflammation–fibrosis–fistulisation sequence. However, despite the development of novel biological therapies, average efficacy at 1 year remains at 30–50%, with this number decreasing as second-line therapies are regularly required. Currently, new advanced therapies are under investigation to provide alternatives to available treatments. In addition, novel, nonpharmacological strategies are also being explored. Surgical intervention, currently inevitable in a significant proportion of patients, necessitates that prevention of postoperative recurrence is an important research focus and recent studies have shed light on the long-term efficacy of early operative interventions and emerging surgical techniques. Cellular therapies, including stem cell therapy for perianal disease, stem cell transplantation, and harnessing the therapeutic potential of regulatory T cells, are in various stages of development. These could conceivably change the landscape of Crohn’s disease management. Dietetic interventions offer a lower risk alternative that may be used as an adjunct to other therapies or where immunosuppression is unfavourable. Choosing between these therapeutic options depends on multiple factors, including the associated risk–benefit profile, available alternatives, as well as patient preference. In practice, optimal management is guided by a multidisciplinary team where pharmacological, nonpharmacological, and surgical strategies can be simultaneously explored. This narrative review aims to provide an update on advanced therapies under investigation in clinical trials and offer insights into novel, nonpharmacological approaches with a focus on interventions entering late-phase trials that will be relevant to clinical practice in the near future.
topic crohn’s disease
inflammatory bowel disease
treatments/therapies
surgery
url https://www.emjreviews.com/gastroenterology/article/emerging-treatments-for-crohns-disease-cells-surgery-and-novel-therapeutics/
work_keys_str_mv AT susannameade emergingtreatmentsforcrohnsdiseasecellssurgeryandnoveltherapeutics
AT raphaelpluber emergingtreatmentsforcrohnsdiseasecellssurgeryandnoveltherapeutics
AT gokultamilarasan emergingtreatmentsforcrohnsdiseasecellssurgeryandnoveltherapeutics
AT eoindinneen emergingtreatmentsforcrohnsdiseasecellssurgeryandnoveltherapeutics
AT petermirving emergingtreatmentsforcrohnsdiseasecellssurgeryandnoveltherapeutics
AT markasamaan emergingtreatmentsforcrohnsdiseasecellssurgeryandnoveltherapeutics
_version_ 1721537660097396736